Moleculin Biotech Inc (NASDAQ:MBRX) Has Increase in Shorts

June 1, 2018 - By Dolores Ford

The stock of Moleculin Biotech Inc (NASDAQ:MBRX) registered an increase of 1% in short interest. MBRX’s total short interest was 1.50 million shares in June as published by FINRA. Its up 1% from 1.48M shares, reported previously. With 159,000 shares average volume, it will take short sellers 9 days to cover their MBRX’s short positions. The short interest to Moleculin Biotech Inc’s float is 10.53%.

The stock increased 1.23% or $0.0221 during the last trading session, reaching $1.8221. About 128,431 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has risen 88.76% since June 1, 2017 and is uptrending. It has outperformed by 76.19% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $46.95 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More news for Moleculin Biotech, Inc. (NASDAQ:MBRX) were recently published by: Globenewswire.com, which released: “Moleculin Invited to Present to International BioForum 2018 Conference” on May 24, 2018. Globenewswire.com‘s article titled: “Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center” and published on May 16, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.